AP NEWS

Knopp Biosciences to Present at 2019 BIO CEO & Investor Conference

January 30, 2019

PITTSBURGH--(BUSINESS WIRE)--Jan 30, 2019--Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that the management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference, to be held in New York, NY on February 11-12.

Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, February 12 at 11:15 a.m. Eastern Time.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 development in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit www.knoppbio.com.

This press release contains “forward-looking statements,” including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190130005027/en/

CONTACT: Media:

James Heins

james.heins@icrinc.com

646-277-8251

KEYWORD: UNITED STATES EUROPE NORTH AMERICA NEW YORK PENNSYLVANIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL OTHER HEALTH RESEARCH SCIENCE GENERAL HEALTH

SOURCE: Knopp Biosciences

Copyright Business Wire 2019.

PUB: 01/30/2019 06:00 AM/DISC: 01/30/2019 06:00 AM

http://www.businesswire.com/news/home/20190130005027/en

AP RADIO
Update hourly